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Abstract
Background—Timing and trajectories of cardiovascular risk factor (CVRF) development in 
relation to atrial fibrillation (AF) have not been previously described. We assessed trajectories of 
CVRF and incidence of AF over 25 years in the Atherosclerosis Risk in Communities (ARIC) 
study.
Methods—We assessed trajectories of CVRF in 2456 individuals with incident AF and 6414 
matched controls. Subsequently, we determined the association of CVRF trajectories with the 
incidence of AF among 10,559 AF-free individuals (mean age 67, 52% men, 20% blacks). Risk 
factors were measured during 5 exams between 1987-2013. Cardiovascular events, including 
incident AF, were continuously ascertained. We modeled the prevalence of risk factors and 
cardiovascular outcomes in the period before and after AF diagnosis and the corresponding index 
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date for controls using generalized estimating equations. Trajectories in risk factors were identified 
using latent mixture modeling. The risk of incident AF by trajectory group was examined using 
Cox models.
Results—The prevalence of stroke, myocardial infarction, and heart failure increased steeply 
during the time close to AF diagnosis. All CVRFs were elevated in AF cases compared to controls 
>15 years prior to diagnosis. We identified distinct trajectories for all the assessed CVRFs. In 
general, individuals with trajectories denoting long-term exposure to CVRFs had increased AF 
risk even after adjustment for single measurements of the CVRFs.
Conclusion—AF patients have increased prevalence of CVRF many years before disease 
diagnosis. This analysis identified diverse trajectories in the prevalence of these risk factors, 
highlighting their different roles in AF pathogenesis.
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INTRODUCTION
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with a lifetime risk 
of 1 in 4 in the general population and an increasing prevalence as the population ages.1 
Major risk factors for AF include age, white race, obesity, smoking, hypertension, diabetes, 
and a history of myocardial infarction (MI) and heart failure (HF).2-6 These risk factors are 
similar to the risk factors for cardiovascular disease in general, and these cardiovascular 
outcomes often precede an AF event.7 The development of AF is also associated with 
subsequent increased risk of cardiovascular death,8, 9 HF,10 MI,11, 12 and stroke.13
Despite the extensive literature on risk factors for AF, little attention has been devoted to the 
timing of risk factor development in relation to AF diagnosis; exceptions are stroke as an 
outcome of AF, and HF as both a risk factor for and outcome of AF. While it is known that 
AF is a risk factor for stroke and, therefore, most often precedes it,14 AF and HF show a 
bidirectional relation, and the existing severity of specific cardiovascular risk factors, along 
with age and sex, may determine whether AF or HF occurs first.15, 16 However, no 
information exists on the timing, relative to AF diagnosis, of the development of other AF 
risk factors such as hypertension or obesity. This information can be useful to better 
understand the factors that influence the progress of the cardiac substrate facilitating the 
onset of AF and, therefore, develop preventive strategies.
Furthermore, healthcare utilization, particularly cardiovascular-related utilization, is higher 
among patients with AF than among non-AF individuals even after adjusting for 
cardiovascular risk factors.17 Exploring how trajectories in cardiovascular risk factor 
prevalence differ between individuals with and without AF could help to understand 
observed differences in healthcare utilization. Risk factor trajectories could also be clinically 
relevant and informative in the prevention of AF, and may provide more information than a 
one-time measurement. With the overall goal of assessing the association of trajectories of 
cardiovascular risk factors and outcomes with AF, we addressed the following 2 aims: 1) To 
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describe the long term prevalence of risk factors preceding AF diagnosis and the subsequent 
development of cardiovascular outcomes after diagnosis, and compare the risk factors and 
outcomes by AF status; 2) To identify subgroups of individuals with similar trajectories of 
risk factors and outcomes, and determine the association of these trajectory subgroups with 
the subsequent development of AF. The Atherosclerosis Risk in Communities (ARIC) study, 
a population-based study with a 25-year follow-up and a large number of incident AF cases, 




The ARIC study is a mostly biracial, prospective cohort study of cardiovascular disease and 
atherosclerosis risk factors.18 Participants at baseline (1987-1989) included 15,792 men and 
women aged 45-64, recruited from 4 communities in the US (Washington County, 
Maryland; the northwest suburbs of Minneapolis, Minnesota; Jackson, Mississippi; and 
Forsyth County, North Carolina). ARIC participants were mostly white in the Washington 
County and Minneapolis centers, only African-American in the Jackson center, and included 
both races in Forsyth County. After the initial assessment, study participants were examined 
4 additional times (1990-92 (visit 2), 1993-95 (visit 3), 1996-98 (visit 4), 2011-13 (visit 5)). 
Additionally, ARIC participants receive annual follow-up calls, with response rates of ≥ 90% 
among survivors.
Of the 15,792 participants who attended visit 1 in the ARIC study, we excluded individuals 
who were of a racial group other than white or African-American and nonwhites in the 
Minneapolis and Washington County field centers (n=103), those with prevalent AF at visit 
1 (n=37), and those with low quality or missing ECG (n=242). After exclusions, our study 
population included 15,410 participants (26% African-American, 45% male). For aim 1, our 
analysis included 2456 individuals with AF diagnosed during the follow-up and 6414 
matched controls without AF. For aim 2, we included 10,559 individuals with measured risk 
factors at the first 4 visits, and without prevalent AF at visit 4.
This study was approved by institutional review boards at each participating center and all 
study participants provided written informed consent.
AF ascertainment
AF diagnoses were ascertained by 3 different sources in the ARIC study: electrocardiograms 
(ECG) performed at study visits, hospital discharge codes, and death certificates.3 At each 
ARIC study visit, a 10-second 12-lead ECG was performed using a MAC PC cardiograph 
(Marquette Electronics Inc, Milwaukee, WI) and transmitted to the ARIC ECG Reading 
Center for coding, interpretation and storage. All ECGs automatically coded as AF were 
visually checked by a trained cardiologist to confirm AF diagnosis.19 Annual follow-up calls 
and review of local hospital discharges identified hospitalizations in ARIC participants 
through the end of 2012. International Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM) codes of 427.31 (atrial fibrillation) or 427.32 (atrial flutter) listed 
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as a discharge diagnostic code in any position defined AF cases. AF events associated with 
cardiac surgery were not included in this study. Validity of ICD codes for AF is adequate as 
approximately 90% of the cases were confirmed in a physician review of discharge 
summaries from 125 possible AF cases.3 AF cases were also identified if code ICD-9 427.3 
or International Classification of Diseases, 10th Revision (ICD-10) code I48 was listed as a 
cause of death. In this analysis, the AF incident date was defined as the date of the first ECG 
showing AF (4% of our AF cases), the first hospital discharge with AF coded (96% of AF 
cases), or when AF was listed as a cause of death (0.1% of cases), whichever occurred 
earlier.
Risk factor and outcome ascertainment
At baseline and during follow-up exams, participants reported information on smoking, 
history of cardiovascular disease, use of medications, and underwent a physical exam. Body 
mass index (BMI) was calculated as weight in kilograms divided by height in meters 
squared. Blood pressure was measured using a random-zero sphygmomanometer after 5 
minutes of rest in the sitting position, and was defined as the average of the 2nd and 3rd 
measurements taken. Hypertension was defined as a systolic blood pressure (SBP) ≥ 140 
mmHg or diastolic blood pressure ≥ 90 mmHg or use of anti-hypertensive medications. In 
analysis using continuous SBP, a constant of 10 mmHg was added to the participant’s 
measure if they were taking anti-hypertension medications.20 Diabetes mellitus was defined 
as fasting glucose ≥ 126 mg/dL (7.0 mmol/L), non-fasting glucose ≥ 200 mg/dL (11.1 
mmol/L), treatment for diabetes mellitus, or self-reported physician diagnosis of diabetes. 
Prevalent HF was defined as the reported use of HF medication in the previous two weeks, 
presence of HF according the Gothenburg criteria (only at the baseline visit), or having had a 
HF hospitalization since the previous visit.21 Incident HF was defined as the first occurrence 
of any listing of an ICD-9-CM code 428 for a hospitalization during follow-up.22 Prevalent 
MI at baseline was defined as a self-reported physician-diagnosed MI or presence of a MI by 
ECG, and incident MI was ascertained by study visit ECGs or the ARIC Morbidity and 
Mortality Classification Committee, by using data from follow-up calls, hospitalization 
records and death certificates.23 Prevalent stroke at baseline was defined as the self-reported 
physician diagnosis of a stroke prior to visit 1, and incident stroke was defined as the sudden 
or rapid onset of neurological symptoms lasting for at least 24 hours or leading to death in 
the absence of evidence for a non-stroke cause, and was validated using established criteria 
with physician review of records.24
Covariates measured at baseline (visit 1) included sex, race, and study center. Information on 
smoking, obesity, hypertension, diabetes, HF, MI, stroke, and AF was obtained during each 
of the 5 study exams between 1987 and 2013. AF, HF, MI and stroke also were ascertained 
from annual surveillance.
Statistical analysis
For Aim 1, to assess the prevalence of cardiovascular risk factors and outcomes in persons 
with AF vs. AF-free controls, we compared risk factors and outcomes both before and after 
AF diagnosis to those in individuals without AF. Each AF case was matched with up to 3 
controls by age (± 2 years), sex, race, and field center. We defined index date (time t=0) as 
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the date of AF diagnosis for each case and the same date for the corresponding matched 
controls. Time to each visit was re-calculated in relation to the index date as time at visit i 
(ti) = visit i date − index date (in years). Negative and positive values correspond to exams 
before and after the study index date, respectively.
Using a dataset with one observation per person-visit (maximum 5 observations per 
participant), we fit generalized estimating equation (GEE) models with a logistic link with 
time in years before/after index date as the main independent variable. Time was categorized 
in 5-year periods (<−17.5, −17.5 to <−12.5, −12.5 to <−7.5, -7.5 to <−2.5, −2.5 to +2.5 
(reference), and >+2.5 years). We chose a reference time of ± 2.5 years to account for 
imprecise AF diagnosis, and chose 5 year increments for easy descriptive purposes. Separate 
models were used to predict the prevalence of risk factors and cardiovascular outcomes 
(hypertension, smoking, obesity, diabetes, HF, MI, and stroke) in each time period separately 
for AF cases and controls and by race. To describe the changes in risk factors and 
cardiovascular outcomes over time in those with and without AF, adjusted odds ratios (OR) 
were calculated using the same GEE models, and also using the index date ±2.5 years as the 
reference group. The interaction of time with AF status was used to test for differences in 
the OR trajectories in cases and controls.
For Aim 2, we included 10,559 individuals with measurements at the first 4 visits (during 
years 1987-1998) and without AF at the time of visit 4, and identified risk factor trajectories 
during those years. Then we determined the association of each trajectory with the risk of 
incident AF through the end of 2013. We used latent class models to identify distinct 
subgroups within the ARIC cohort sharing a similar underlying trajectory for each risk 
factor. These models were fit using SAS Proc Traj.25-27 The supplemental materials include 
additional details on the trajectory modeling process. The association of each trajectory 
group with the risk of incident AF was modeled using Cox proportional hazards models 
comparing the risk in each trajectory group with the reference trajectory group. Models were 
adjusted for age, sex, race, and each of the other risk factors (BMI, smoking, diabetes, 
hypertension, and a history of MI, HF or stroke) measured at visit 4. An additional model 
adjusted for the measure of the continuous variable risk factor at visit 4 to determine if the 
previous trajectory itself provided more predictive information on the association with AF 
than a one-time measurement. This additional adjustment was possible for BMI, SBP, and 
current smoking, but not for diabetes, HF, MI, or stroke due to model fit issues derived from 
complete separation of the data. Follow-up time for Cox models began at visit 4, and 
continued until the date of AF, the end of follow-up (2013), death, or the date of last contact. 
All statistical analyses were performed with SAS v 9.3 (SAS Inc, Cary, NC).
RESULTS
For Aim 1, during a median follow-up of 24 years (interquartile range = 20.5-25.0 years), 
2456 cases of AF were detected (19% black race; 54% male), and matched with 6414 
controls without AF. Characteristics of AF cases and controls at the index date are included 
in table 1. Compared to controls, AF cases had higher BMI and greater prevalence of current 
smoking, hypertension, diabetes, HF, MI and stroke. The mean number of visits attended by 
Norby et al. Page 5













AF cases and matched controls was 3.8 and 4.1, respectively. The mean calendar year of AF 
diagnosis was 2003.
The age and sex-adjusted prevalence of risk factors and cardiovascular outcomes by AF 
status and race is depicted in Figure 1. Cardiovascular risk factors and outcomes were more 
prevalent in AF cases than in matched controls. This increased prevalence was present for all 
risk factors and outcomes from the beginning of follow-up, and was significantly higher for 
obesity, smoking and HF even in the period <−17.5 years before index date (p<0.05). Blacks 
with AF had the highest prevalence for each risk factor and cardiovascular outcome both 
before and after developing AF, while the prevalences were lowest in white controls. For 
both race groups, the prevalence of hypertension and diabetes increased gradually over time, 
up to and after the index date. The prevalence of smoking and obesity increased slightly 
during follow-up but started to decline around the index date. The prevalence of HF, stroke 
and MI in AF cases had a J-shape pattern, with low prevalence in the 10+ years before AF, 
and steep increases in prevalence during the period of time close to AF diagnosis. The 
prevalence of HF, stroke and MI in controls remained low throughout follow-up for both 
blacks and whites.
Figure 2 depicts the change in the prevalence of risk factors and cardiovascular outcomes in 
AF cases, adjusted for age, race and sex. We observed diverse odds ratio trajectories in the 
prevalence of risk factors and cardiovascular outcomes among AF patients, with steep 
increases in the prevalence of stroke, MI and HF during the time period closest to AF 
diagnosis. Odds ratio trajectories for hypertension and diabetes showed monotonic increases 
over time, and those for smoking and obesity suggested decreases after AF diagnosis. An 
odds ratio <1 or >1 can be interpreted as a lower or higher odds, respectively, of the 
corresponding risk factor or outcome at a particular time period compared with the odds at 
the time of AF diagnosis date. The odds of having HF around 10 years prior to AF diagnosis 
is approximately 50% lower when compared to having HF at the time of AF, whereas the 
odds of having diabetes or hypertension is only about 20% lower 10 years prior to AF. The 
odds ratios over time for hypertension, obesity, HF, stroke and MI were significantly 
different based on AF status (p<0.05 for all the interaction terms), with lower increments 
among those without AF.
For aim 2, trajectories for each of the cardiovascular risk factors and outcomes were fit to 
the 10,559 participants who participated in the first 4 visits and were free of AF at visit 4. 
These trajectories are depicted in Figure 3. Five distinct trajectories were identified for BMI, 
obesity, and SBP, and 4 distinct trajectories were identified for hypertension, smoking, 
diabetes, HF, MI and stroke. The trajectory analysis for BMI and SBP identified subsets with 
different baseline values but parallel increases in the values of the risk factor over the 9-year 
period. In contrast, for obesity, hypertension, diabetes, HF, MI and stroke, we identified a 
group without the condition during the 9-year period, a group with prevalence close to 100% 
during the follow-up, and 2 or 3 intermediate groups in which the prevalence increased at 
different rates during the 9-year period. For smoking, the trajectory analysis identified a 
group of non-smokers (77% of the cohort), a group of long-term current smokers (11% of 
the cohort), and 2 smaller groups that quit smoking at similar rates.
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During follow-up of these trajectory groups (median follow-up = 15 years), 1507 cases of 
incident AF were detected. The association of each trajectory group for each risk factor and 
outcome is presented in table 2. For each risk factor, the trajectory group with the most 
favorable profile (group 1) was the reference to which the other trajectory groups were 
compared. For all risk factors, risk of incident AF was highest among individuals in the 
trajectory group with the highest prevalence of risk factor values and lowest in the reference 
trajectory group. The long-term obese (obesity trajectory group 5), had a 39% (95% 
confidence interval [CI], 14-70%) increased risk of AF compared to the reference trajectory 
group (non-obese), even after adjusting for BMI measured at visit 4. Similarly, the SBP 
trajectory groups with high and very high long-term SBP, who had average SBP >140 for >9 
years, had an increased risk of AF, even after adjustment for SBP measured at visit 4. These 
results were consistent with the hypertension analysis, in which hypertension trajectory 
group 4 (long-term hypertensives) had a HR (95% CI) of 1.31 (1.14-1.51) compared to the 
reference group, even after adjustment for visit 4 SBP. Compared with long-term non-
smokers (smoking trajectory group 1), the long-term current smokers (trajectory group 4) 
had increased risk of AF, even after adjusting for smoking status at visit 4. The risk of AF 
among those who quit (trajectory groups 2 and 3) was intermediate. The risk of AF was 
higher in the trajectories containing participants with long-term (trajectory group 4) or newly 
diagnosed (trajectory groups 2 and 3) diabetes, HF, MI and stroke compared to those without 
the disease (trajectory group 1).
DISCUSSION
In this large population-based study describing the timing of risk factors and outcomes in 
relation to AF diagnosis, we observed diverse trajectories in the prevalence of risk factors 
and cardiovascular outcomes. We also found that trajectories of risk factors are associated 
with the future risk of AF, providing additional information beyond that obtained from 
single risk factor measurements. In the first aim, there were steep increases in the prevalence 
of stroke, MI and HF during the years proximal to the AF diagnosis, while prevalences for 
hypertension and diabetes showed monotonic increases over time, and those for smoking 
and obesity suggested decreases in prevalence after AF diagnosis. The odds ratios over time 
for hypertension, obesity, HF, stroke and MI were significantly different based on AF status, 
with lower increments among those without AF. Also, we found that the prevalence of most 
cardiovascular risk factors was higher in individuals with AF compared to AF-free controls 
even 15 years or more before the diagnosis of AF. In Aim 2, we observed that those with 
prevalent risk factors, and those that have had them for a longer duration, had an increased 
risk of AF. Participants with high blood pressure or who have been obese for a longer period 
of time have an even higher risk, and the time since onset may be important. These results 
underscore the role of factors such as hypertension and obesity in contributing to the 
development of the atrial substrate that eventually leads to the clinical onset of AF, and the 
need to act earlier in the pathogenic process to be able to prevent this common arrhythmia.
Few studies have considered the timing of risk factor development in relation to AF 
diagnosis. Most current information consists of the well-known association of increased 
stroke risk following an AF event,14 and for this reason, the 2014 ACC/AHA/HRS 
Guideline for the Management of Patients with AF recommend oral anticoagulation in 
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patients with a moderate or greater risk of ischemic stroke.28 The studies that address the 
timing of AF and HF development show a bidirectional association, and the existing severity 
of specific cardiovascular risk factors such as BMI, diabetes and previous MI, along with 
age and sex, may determine whether AF or HF occurs first in the individual. 15, 16 Which 
event develops first also may be indicative of the overall health of the patient, as it has been 
shown that among hospitalized patients with both AF and HF, AF more frequently 
developed first.29 HF onset in patients with previous AF has been associated with an 
increased risk of morbidity and mortality.16, 30
Though less documented, it appears MI and AF also can occur concurrently. In a meta-
analysis, AF onset in MI patients is associated with higher mortality, (odds ratio (95% 
confidence interval) = 1.46 (1.35-1.58)), and this worse prognosis persisted regardless of the 
timing of AF, suggesting that AF is a major adverse health event for those with MI.31, 32 
Several other studies have shown that AF is associated with an increased risk of MI,11, 33 
particularly non-ST elevation MI, and that this association was stronger in women.12
While stroke, MI and HF are all relatively discrete cardiovascular events, with the highest 
prevalence following AF diagnosis, the trajectories in prevalence of traditional risk factors 
such as hypertension and diabetes are much different, showing monotonic increases over 
time. Both hypertension and diabetes are associated with increased risk of AF, independent 
of other risk factors, and the trajectories depicted in this analysis corroborate that the long-
term effects of each chronic condition could take many years, even decades, to appear. 
Several mechanisms have been proposed to explain the role of hypertension as a risk factor 
for AF over time. Chronic increased systemic blood pressure leads to left ventricular 
hypertrophy, impaired ventricular filling, left atrial enlargement, and slowing of atrial 
conduction velocity.34 High blood pressure causes structural and functional changes in the 
myocardium, leading to an increased risk of arrhythmia.35 Similarly, the damaging impact of 
diabetes on AF risk occurs after prolonged exposure to diabetes, and several mechanisms 
have been proposed. Diabetes could place metabolic stress on the atrium or through 
association with systemic illnesses such as infection or renal failure.36 Also, high HbA1c 
levels and the severity of diabetes and long-term cumulative exposure to hyperglycemia 
could induce AF.37 Several other theories involve atrial dilation, elevated inflammation 
factors such as C-reactive protein, and electrical remodeling of atria.38
Obesity is associated with higher risk of AF, possibly through increased risk of diabetes and 
hypertension, and through the association of high body mass with the metabolic syndrome, 
chronic inflammation, and stress. Obesity also increases atrial size and is associated with left 
ventricular hypertrophy.34, 35 Smoking also is associated with AF in both current and former 
smokers and the association is higher in those with more pack years.7, 39 Nicotine increases 
heart rate and blood pressure, and smoking causes decreased lung function and leads to 
chronic obstructive pulmonary disorder, which are also risk factors for AF. 4, 39 In this 
analysis, we see a higher prevalence of smoking and obesity in AF cases throughout the 
entire follow-up, increasing slightly over time up to AF diagnosis and then decreasing 
around the time of AF and afterwards. This decrease could be due to either health issues 
causing weight loss, or a diagnosis of AF instigating lifestyle changes leading to weight loss 
and smoking cessation.
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As previously shown in the ARIC study, AF is more common in whites than in blacks, 
despite the higher prevalence of co-morbidities and cardiovascular outcomes in blacks.3 This 
new analysis reports a higher prevalence of all risk factors and cardiovascular outcomes in 
blacks with AF or without AF compared to their white counterparts throughout the entire 
follow-up, with the highest prevalence in blacks with AF.
This study describing the prevalence and trajectories of cardiovascular risk factors and 
outcomes in AF cases has relevant clinical and public health implications. First, it reinforces 
the concurrent nature of cardiovascular events such as HF, MI and stroke as major adverse 
events that tend to cluster around the time of AF. For newly diagnosed AF cases, treatment 
should involve the prevention and early detection of these other cardiovascular events. For 
patients with previous MI or HF, prevention and early detection of AF could lead to better 
outcomes. Second, this study implies that chronic conditions, such as diabetes, hypertension, 
smoking and obesity cause damage to the cardiovascular system over an extended amount of 
time. Targeting these upstream risk factors could prevent AF in addition to other 
cardiovascular diseases; treatment for these conditions should emphasize long-term control 
to minimize the risks of eventual cardiovascular events, such as AF. The decreased risk of 
AF in former smokers compared to current smokers could have clinical implications, and 
future studies should explore the effects of improvement in risk factors, including smoking 
cessation, on the risk of AF. Third, the timing of cardiovascular risk factors and outcomes, 
relative to AF diagnosis, is useful to better understand the pathogenesis of AF, and should be 
used to further causation theories and to develop preventive strategies. Fourth, the distinct 
trajectory groups could contribute to identify subsets of AF patients with shared etiology and 
pathophysiologic mechanisms, which may result in more targeted treatments and preventive 
strategies. Lastly, these trajectories could be used to help explain observed differences in 
healthcare utilization in those with and without AF, and can be used to develop plans for 
healthcare resource allocation.
Limitations of this study include possible misclassification of the HF and AF diagnoses, 
which were based mostly on ICD discharge codes. Similarly, outpatient AF cases were not 
captured, so it is possible that some paroxysmal/intermittent AF cases were undetected. Bias 
may also occur if AF was detected as an incidental finding during a hospitalization for some 
other reason, such as a cardiovascular event. However, it has been shown that AF diagnosed 
by ICD codes and from study visit ECGs has a positive predictive value of ~90%,3 and 
validity of HF in ARIC is ~90%.40 For aim 1, we used AF diagnosis date ± 2.5 years to 
capture the time period around the diagnosis, since participants could have episodes of AF 
occurring before they were diagnosed. Selection bias is a concern, particularly after the 
index date, as those who live longer may have an overall healthier cardiovascular profile 
compared to someone who died shortly after AF.
Despite these limitations, our study has numerous key strengths. This is a large community-
based cohort, with a biracial sample, repeat study visits with comparable assessment of risk 
factors over time, and long-term annual follow-up, giving us the ability to observe health 
trends over 25 years. There are a large number of cardiovascular and AF events with good 
quality data on risk factors and detailed ascertainment and adjudication of cardiovascular 
risk factors and outcomes.
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In this large population-based study, we report increased prevalence of cardiovascular risk 
factors in AF patients more than 15 years before their diagnosis. The prevalence of 
cardiovascular outcomes increased after AF diagnosis, and trajectories differed by AF status. 
We also found diverse trajectories in the prevalence of risk factors and cardiovascular 
outcomes, suggesting they could have different roles in the pathogenesis of AF.
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• Using follow-up from a large community-based cohort, we assessed the 
prevalence of cardiovascular risk factors and atrial fibrillation (AF)-
related outcomes over time by AF status, and explored the association 
of trajectories of risk factors with incident AF. Stroke, myocardial 
infarction and heart failure prevalence increased steeply around the 
time of AF, while monotonic increases in hypertension and diabetes 
prevalence over many years were associated with AF risk.
• A trajectory analysis showed that not only presence of risk factors such 
as hypertension and obesity, but also their duration was more 
informative in determining AF risk compared to 1-time clinical 
measurements.
What are the clinical implications?
• Exploring the timing and trajectories of risk factor development in 
relation to AF diagnosis could provide insights into the pathogenesis of 
this common arrhythmia and inform prevention strategies.
• This large, community-based study with 25 years of follow-up 
demonstrated an increased prevalence of cardiovascular risk factors in 
AF patients many years before disease diagnosis and identified diverse 
trajectories in the prevalence of these risk factors, highlighting their 
different roles in AF pathogenesis, and the need to establish preventive 
strategies that address risk factors decades before AF diagnosis.
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Predicted prevalence of cardiovascular risk factors and outcomes over time by AF status, 
ARIC, 1987-2011. Adjusted prevalence was modeled using general estimating equations 
held constant for age, race and sex. Predicted probabilities of cardiovascular risk factors and 
outcomes were then calculated based on a 65 year old male, stratified by race.
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Odds ratios (OR) of cardiovascular risk factors and outcomes over time, based on AF status, 
adjusted for age, race and sex. OR <1 or >1 can be interpreted as a lower or higher odds, 
respectively, of the risk factor or cardiovascular outcome at a particular time period 
compared with the odds at the time of AF diagnosis date.
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Trajectories in risk factors and outcomes over time, ARIC, 1987-1998. Groups are trajectory 
groups (percentage of the population in each group).
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Table 1
Prevalent characteristics in AF cases at the time of AF diagnosis, and in matched controls at the corresponding 





Calendar year of diagnosis / Index date 2003 (6.6) 2003 (6.6)
Matched variables
 Age, years 66.7 (8.7) 67.4 (8.4)
 Black race, % 18.9 20.5
 Male sex, % 53.6 51.2
Other variables
 Obese, (BMI > 30) % 35.1 28.5
 BMI, kg/m2 28.9 (5.9) 28.0 (5.1)
 Current smoker, % 17.3 14.3
 Hypertension, % 69.8 57.4
 Systolic blood pressure, mmHg 130.0 (21.9) 128.5 (19.7)
 Diastolic blood pressure, mmHg 70.5 (12.5) 69.6 (10.8)
 Diabetes, % 32.3 22.4
 Heart Failure, % 25.3 5.0
 Myocardial infarction, % 19.7 8.3
 Stroke, % 8.2 3.4
*Values correspond to mean (SD) unless otherwise noted
† AF, atrial fibrillation; BMI, body mass index
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Table 2
Adjusted hazard ratios (95% confidence intervals) of atrial fibrillation by risk factor trajectory groups, ARIC, 
1998-2013.
Trajectory groups
Risk factor 1 2 3 4 5
BMI Normal weight Overweight Overweight/obese Obese Extremely obese
  N, % 2607 (25%) 4025 (38%) 2548 (24%) 1086 (10%) 293 (3%)
  # AF 325 535 401 187 59
  Model 1 1 (REF) 0.98 (0.85-1.12) 1.33 (1.14-1.55) 1.66 (1.37-2.01) 2.56 (1.91-3.43)
  Model 1 + V4 BMI 1 (REF) 0.90 (0.75-1.07) 1.13 (0.87-1.47) 1.28 (0.86-1.90) 1.70 (0.92-3.14)
Obesity (≥30) Non-obese Low-increasing Moderate-increasing Moderate long-
term obese
Long-term obese
  N, % 6615 (63%) 292 (3%) 605 (6%) 802 (8%) 2245 (21%)
  # AF 837 57 87 100 426
  Model 1 1 (REF) 1.03 (0.78-1.35) 1.35 (1.08-1.69) 1.18 (0.96-1.45) 1.68 (1.48-1.91)
  Model 1 + V4 BMI 1 (REF) 0.93 (0.70-1.23) 1.21 (0.95-1.54) 1.07 (0.86-1.34) 1.39 (1.14-1.70)
SBP Very low-stable Low-stable Borderline High long-term Very high long-term
  N, % 1464 (14%) 3773 (36%) 3228 (31%) 1713 (16%) 381 (4%)
  # AF 170 450 490 312 85
  Model 1 1 (REF) 1.02 (0.86-1.22) 1.32 (1.11-1.59) 1.73 (1.42-2.10) 2.52 (1.92-3.30)
  Model 1 + V4 SBP 1 (REF) 0.96 (0.79-1.16) 1.16 (0.93-1.46) 1.43 (1.08-1.89) 1.94 (1.32-2.86)
Hypertension Normotensive Low-increasing Moderate-increasing Long-term hypertensive
  N, % 5321 (50%) 878 (8%) 866 (8%) 3494 (33%)
  # AF 583 178 99 647
  Model 1 1 (REF) 1.43 (1.21-1.70) 1.30 (1.04-1.61) 1.57 (1.39-1.77)
  Model 1 + V4 SBP 1 (REF) 1.23 (1.02-1.47) 1.10 (0.88-1.39) 1.31 (1.14-1.51)
Current smoking Non-smoker Early quitters Later quitters Long-term current smokers
  N, % 8175 (77%) 439 (4%) 743 (7%) 1202 (11%)
  # AF 1116 50 132 209
  Model 1 1 (REF) 1.22 (0.92-1.63) 1.57 (1.31-1.88) 1.78 (1.53-2.07)
  Model 1 + V4
  current smoking
1 (REF) 1.23 (0.92-1.64) 1.48 (1.21-1.81) 1.43 (1.03-2.00)
Diabetes Non-diabetics Low-increasing Moderate-increasing Long-term diabetes
  N, % 8497 (80%) 328 (3%) 529 (5%) 1205 (11%)
  # AF 1096 85 91 235
  Model 1 1 (REF) 1.29 (1.03-1.62) 1.28 (1.03-1.59) 1.57 (1.36-1.82)
Heart failure No heart failure Low-increasing Moderate-increasing Long-term heart failure
  N, % 10,066 (95%) 77 (1%) 60 (1%) 356 (3%)
  # AF 1368 29 22 88
  Model 1 1 (REF) 1.91 (1.31-2.78) 3.06 (1.99-4.70) 1.59 (1.27-1.98)
MI No MI Low-increasing Moderate-increasing Long-term MI
  N, % 10,035 (95%) 84 (1%) 120 (1%) 320 (3%)
  # AF 1360 29 34 84
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Trajectory groups
Risk factor 1 2 3 4 5
  Model 1 1 (REF) 1.82 (1.25-2.64) 2.02 (1.43-2.85) 1.77 (1.41-2.21)
Stroke No stroke Low-increasing Moderate-increasing Long-term stroke
  N, % 10,229 (97%) 74 (1%) 76 (1%) 180 (2%)
  # AF 1434 19 17 37
  Model 1 1 (REF) 1.37 (0.87-2.16) 1.57 (0.96-2.54) 1.68 (1.21-2.33)
Model 1 adjusted for age, sex, race, BMI, smoking, diabetes, hypertension, history of MI, history of heart failure, history of stroke where 
appropriate
BMI, body mass index; SBP, systolic blood pressure; AF, atrial fibrillation; V4, visit 4; HF, heart failure; MI, myocardial infarction
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